絞り込み

16385

広告

[Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation].

著者 Helms TM , Gulba D , Ahrens I , Schäfer A , Hankowitz J , Kuhlencordt P , Lipp HP , Nikol S , Riess H , Stargardt T , Bramlage P
Dtsch Med Wochenschr.2017 Apr 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (82view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

With the recent approval of the fourth direct non vitamin K dependent oral anticoagulant (NOAC) edoxaban the range of available NOACs for the treatment of venous thromboembolism (VTE) has expanded. Shortly thereafter, two updated guidelines for the prevention and treatment of VTE have been published. In these NOACs are listed as equal anticoagulants to low-molecular weight heparin (LMWH), or fondaparinux (FDX), and VKA for the initial or maintenance treatment of VTE. All NOACs are approved for the maintenance therapy after VTE and two NOACs (rivaroxaban and apixaban) for the initial treatment in addition in an increased dose.NOACs differ in their pharmacodynamic and pharmacokinetic properties. In patients with renal insufficiency the dose of all NOACs should be reduced similarly to NMH/FDX. In contrast to VKAs, bridging with NOACs in case of surgical interventions is generally dispensable. Similar to NMHs or FPX renal function and individual bleeding risk dependent dose intermission is generally sufficient. Conventional coagulation parameters like aPTT and INR are not suitable for the monitoring of NOACs. Only in seldom cases, laboratory monitoring with use of adjusted anti-Xa testing or diluted thrombin time (dabigatran) may be helpful.
PMID: 28423431 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード